Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NEO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NEO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Tony Zook | $601,539 | $0 | $3,999,997 | $3,998,235 | $513,400 | $0 | $13,921 | $9,127,092 |
| Director and Chief Executive Officer | ||||||||
| Warren Stone | 630,069 | 400,000 | 2,249,994 | 1,499,767 | 275,000 | 0 | 14,000 | 5,068,830 |
| President and Chief Operating Officer | ||||||||
| Jeffrey Sherman | 603,731 | 50,000 | 2,250,000 | 1,499,697 | 264,000 | 0 | 14,000 | 4,681,428 |
| Chief Financial Officer | ||||||||
| Christopher Smith | 310,962 | 0 | 3,350,004 | 0 | 155,754 | 0 | 229,217 | 4,045,937 |
| Former Director and Former Chief Executive Officer | ||||||||
| Melody Harris | 269,231 | 152,329 | 1,666,652 | 912,848 | 0 | 0 | 691,385 | 3,692,445 |
| Former Chief Operations Officer and President, Oncology Data Solutions | ||||||||
| Alicia Olivo | 522,500 | 75,000 | 1,499,997 | 749,848 | 196,000 | 0 | 6,654 | 3,049,999 |
| Executive Vice President, General Counsel & Business Development | ||||||||
| Gary Passman | 447,962 | 75,000 | 1,124,995 | 624,876 | 164,000 | 0 | 6,362 | 2,443,195 |
| Chief Culture Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Tony Zook | $9,127,092 | — | — | — |
| Warren Stone | 5,068,830 | 3,184,486 | — | +1,884,344 |
| Jeffrey Sherman | 4,681,428 | 3,482,409 | — | +1,199,019 |
| Christopher Smith | 4,045,937 | 11,338,487 | — | −7,292,550 |
| Melody Harris | 3,692,445 | 2,875,377 | — | +817,068 |
| Alicia Olivo | 3,049,999 | 2,236,859 | — | +813,140 |
| Gary Passman | 2,443,195 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Greg D. Aunan | Chief Accounting Officer | 2026-05-01 | D | 1,309 | $0 | $0 | Common | Form 4 ↗ |
| Greg D. Aunan | Chief Accounting Officer | 2026-05-01 | D | 5,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Greg D. Aunan | Chief Accounting Officer | 2026-05-01 | A | 5,372 | 0 | 0 | Common | Form 4 ↗ |
| Alicia Olivo | EVP, GC & Business Development | 2026-05-01 | D | 1,042 | 0 | 0 | Common | Form 4 ↗ |
| Greg D. Aunan | Chief Accounting Officer | 2026-05-01 | D | 937 | 0 | 0 | Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-02 | D | 2,349 | 0 | 0 | Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-02 | D | 5,969 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-02 | A | 5,969 | 0 | 0 | Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-11 | A | 5,830 | 0 | 0 | Common | Form 4 ↗ |
| Alicia Olivo | EVP, GC & Business Development | 2026-05-11 | A | 3,944 | 0 | 0 | Common | Form 4 ↗ |
| Alicia Olivo | EVP, GC & Business Development | 2026-05-11 | D | 2,559 | 0 | 0 | Common | Form 4 ↗ |
| Alicia Olivo | EVP, GC & Business Development | 2026-05-11 | D | 3,944 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-11 | D | 5,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Warren Stone | Pres & Chief Operating Officer | 2026-05-11 | D | 3,783 | 0 | 0 | Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Perez | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Perez | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Perez | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kelly | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Marjorie Green | Director | 2026-06-01 | A | 22,964 | 0 | 0 | Common | Form 4 ↗ |
| Felicia Williams | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kelly | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Neil Gunn | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Dr. Neil Gunn | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kelly | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Jack Kenny | Director | 2026-06-01 | D | 5,893 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kenny | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Felicia Williams | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Kanovsky | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Neil Gunn | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Neil Gunn | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Kanovsky | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Marjorie Green | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Marjorie Green | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Perez | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Michael Kelly | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Kanovsky | Director | 2026-06-01 | A | 23,077 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Kanovsky | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dr. Marjorie Green | Director | 2026-06-01 | D | 22,964 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Kenny | Director | 2026-06-01 | A | 5,893 | 0 | 0 | Common | Form 4 ↗ |
| Jack Kenny | Director | 2026-06-01 | A | 11,069 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Felicia Williams | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Felicia Williams | Director | 2026-06-01 | A | 15,970 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-01 | D | 23,077 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-09 | D | 5,307 | 11 | 59,916 | Common | Form 4 ↗ |
| Lynn Tetrault | Director | 2026-06-15 | D | 5,307 | 11 | 58,908 | Common | Form 4 ↗ |
| Carolyn S. Starrett | Director | 2026-06-23 | A | 14,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carolyn S. Starrett | Director | 2026-06-23 | A | 9,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gary Passman | PSU | — | 39,588 | 271,200 | — | 325,440 | $499,996 |
| Melody Harris | RSU | — | — | — | 134,034 | — | 1,666,652 |
| Tony Zook | PSU | — | 421,496 | 850,000 | — | 1,700,000 | 3,999,997 |
| Jeffrey Sherman | OPTION | — | — | — | 214,900 | — | 1,499,697 |
| Alicia Olivo | OPTION | — | — | — | 107,450 | — | 749,848 |
| Gary Passman | RSU | — | — | — | 52,698 | — | 624,998 |
| Warren Stone | OPTION | — | — | — | 94,518 | — | 499,973 |
| Tony Zook | OPTION | — | — | — | 729,927 | — | 3,998,235 |
| Warren Stone | RSU | — | — | — | 84,317 | — | 1,000,000 |
| Warren Stone | OPTION | — | — | — | 143,266 | — | 999,794 |
| Christopher Smith | PSU | — | 265,452 | 1,050,000 | — | 2,100,000 | 3,350,004 |
| Jeffrey Sherman | PSU | — | 59,382 | 437,500 | — | 612,500 | 749,995 |
| Warren Stone | PSU | — | 59,382 | 455,000 | — | 637,000 | 749,995 |
| Alicia Olivo | RSU | — | — | — | 63,238 | — | 750,003 |
| Gary Passman | OPTION | — | — | — | 89,542 | — | 624,876 |
| Jeffrey Sherman | RSU | — | — | — | 126,476 | — | 1,500,005 |
| Warren Stone | RSU | — | — | — | 52,687 | — | 499,999 |
| Melody Harris | PSU | — | — | 132,162 | — | 4 | 912,848 |
| Alicia Olivo | PSU | — | 59,382 | 324,000 | — | 388,800 | 749,995 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gary Passman | $624,998 | $499,996 | $624,876 | 28.6% |
| Melody Harris | 1,666,652 | 912,848 | 0 | 35.4% |
| Tony Zook | 0 | 3,999,997 | 3,998,235 | 50.0% |
| Jeffrey Sherman | 1,500,005 | 749,995 | 1,499,697 | 20.0% |
| Alicia Olivo | 750,003 | 749,995 | 749,848 | 33.3% |
| Warren Stone | 1,499,999 | 749,995 | 1,499,767 | 20.0% |
| Christopher Smith | 0 | 3,350,004 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Warren Stone | RSU | 59,382 | — | $698,332 |
| Warren Stone | RSU | 16,886 | — | 198,579 |
| Alicia Olivo | PSU | 12,665 | — | 148,940 |
| Warren Stone | Option | 26,204 | 16.45 | — |
| Alicia Olivo | Option | 16,140 | 16.45 | — |
| Warren Stone | RSU | 11,939 | — | 140,403 |
| Warren Stone | RSU | 8,954 | — | 105,299 |
| Warren Stone | RSU | 84,317 | — | 991,568 |
| Alicia Olivo | RSU | 6,503 | — | 76,475 |
| Alicia Olivo | RSU | 63,238 | — | 743,679 |
| Jeffrey Sherman | PSU | 39,016 | — | 458,828 |
| Gary Passman | Option | 25,972 | 16.45 | — |
| Gary Passman | Option | 89,542 | 13.05 | — |
| Gary Passman | RSU | 52,698 | — | 619,728 |
| Jeffrey Sherman | Option | 214,900 | 13.05 | — |
| Warren Stone | Option | 19,984 | 13.96 | — |
| Alicia Olivo | Option | 13,833 | 10.05 | — |
| Warren Stone | RSU | 52,687 | — | 619,599 |
| Gary Passman | RSU | 39,588 | — | 465,555 |
| Jeffrey Sherman | Option | 24,339 | 19.65 | — |
| Jeffrey Sherman | RSU | 13,006 | — | 152,951 |
| Gary Passman | RSU | 12,723 | — | 149,622 |
| Gary Passman | PSU | 11,651 | — | 137,016 |
| Warren Stone | Option | 94,518 | 10.44 | — |
| Jeffrey Sherman | Option | 62,293 | 11.62 | — |
| Warren Stone | Option | 143,266 | 13.05 | — |
| Alicia Olivo | Option | 12,170 | 19.65 | — |
| Jeffrey Sherman | RSU | 126,476 | — | 1,487,358 |
| Gary Passman | RSU | 15,972 | — | 187,831 |
| Warren Stone | Option | 41,529 | 11.21 | — |
| Alicia Olivo | Option | 5,556 | 9.45 | — |
| Jeffrey Sherman | RSU | 11,151 | — | 131,136 |
| Alicia Olivo | RSU | 6,841 | — | 80,450 |
| Warren Stone | Option | 17,990 | 19.65 | — |
| Alicia Olivo | Option | 107,450 | 13.05 | — |
| Warren Stone | RSU | 22,302 | — | 262,272 |
| Jeffrey Sherman | PSU | 23,303 | — | 274,043 |
| Melody Harris | RSU | 138,013 | — | 1,601,153 |
| Alicia Olivo | RSU | 59,382 | — | 698,332 |
| Jeffrey Sherman | RSU | 59,382 | — | 698,332 |
| Alicia Olivo | RSU | 8,977 | — | 105,569 |
| Jeffrey Sherman | RSU | 23,303 | — | 274,043 |
| Alicia Olivo | RSU | 16,886 | — | 198,579 |
| Warren Stone | RSU | 12,665 | — | 148,940 |
| Warren Stone | PSU | 12,665 | — | 148,940 |
| Alicia Olivo | RSU | 12,665 | — | 148,940 |
| Gary Passman | RSU | 11,651 | — | 137,016 |
| Warren Stone | PSU | 8,954 | — | 105,299 |
| Jeffrey Sherman | RSU | 31,071 | — | 365,395 |
| Jeffrey Sherman | PSU | 22,302 | — | 262,272 |
| Warren Stone | PSU | 21,204 | — | 249,359 |
| Alicia Olivo | PSU | 19,508 | — | 229,414 |
| Gary Passman | RSU | 15,536 | — | 182,703 |
| Warren Stone | RSU | 9,613 | — | 113,049 |
| Alicia Olivo | RSU | 2,646 | — | 31,117 |
| Jeffrey Sherman | Option | 49,916 | 16.45 | — |
| Gary Passman | Option | 30,588 | 11.74 | — |
Our compensation philosophy provides our executive officers with compensation and benefits that are competitive in the market in which we compete for talent and that meet our goals of attracting, retaining, and motivating highly skilled management, which is necessary to create long-term value for our stockholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | WTW |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 91,781,833 | 18,534,236 | 56,118 | 83.2% | Passed |
| 2025 | 2025-05-22 | 87,823,189 | 19,573,234 | 103,117 | 81.77% | Passed |
| 2024 | 2024-05-23 | 76,045,753 | 33,308,929 | 719,851 | 69.54% | Passed |
| 2023 | 2023-05-25 | 54,790,033 | 47,993,647 | 2,998,666 | 53.31% | Passed |
| 2022 | 2022-06-02 | 29,671,036 | 66,847,771 | 510,791 | 30.74% | Failed |
| 2021 | 2021-05-27 | 90,931,692 | 8,059,423 | 229,266 | 91.86% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 83.2%a |
| 2025 | 2025-05-22 | 81.77%b |
| 2024 | 2024-05-23 | 69.54%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of voting on this Proposal 3.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 1.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 1.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 93 : 1 |
|---|---|
| CEO total compensation | $9,375,553 |
| Median employee compensation | $101,144 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Alison HannahIndependent · Compliance (Chair) · Innovation, Pipeline and Technology · Nominating and Corporate Governance · Departed during FY | $65,842 | $276,231 | $76,511 | $0 | $0 | $418,584 |
| Lynn TetraultIndependent · Board Chair · Culture and Compensation · Nominating and Corporate Governance | 125,150 | 168,000 | 72,000 | 0 | 0 | 365,150 |
| Michael KellyIndependent · Audit and Finance (Chair) · Culture and Compensation | 79,675 | 168,000 | 72,000 | 0 | 0 | 319,675 |
| David PerezIndependent · Culture and Compensation (Chair) · Audit and Finance · Innovation, Pipeline and Technology | 79,300 | 168,000 | 72,000 | 0 | 0 | 319,300 |
| Dr. Neil GunnIndependent · Innovation, Pipeline and Technology (Chair) · Culture and Compensation · Nominating and Corporate Governance | 72,500 | 168,000 | 72,000 | 0 | 0 | 312,500 |
| Felicia WilliamsIndependent · Audit and Finance · Nominating and Corporate Governance | 65,000 | 168,000 | 72,000 | 0 | 0 | 305,000 |
| Stephen KanovskyIndependent · Nominating and Corporate Governance (Chair) · Compliance | 62,921 | 168,000 | 72,000 | 0 | 0 | 302,921 |
| Elizabeth FloegelIndependent · Audit and Finance · Compliance · Departed during FY | 38,628 | 168,000 | 72,000 | 0 | 0 | 278,628 |
| Dr. Marjorie GreenIndependent · Innovation, Pipeline and Technology · Partial-year service · Newly elected | 28,832 | 159,600 | 68,400 | 0 | 0 | 256,832 |
| Anthony P. ZookEmployee director · Innovation, Pipeline and Technology | 21,200 | — | — | — | 0 | 21,200 |
| Jack KennyIndependent · Innovation, Pipeline and Technology · Partial-year service · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 62,500 / 10,000 |
| Stock ownership guideline | achieve an ownership target of NeoGenomics stock equal to or greater than three times the value of the annual retainer paid to such director |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $639,048 |
| Equity awards (grant-date value) | $1,611,831 |
| All other compensation | $0 |
| Total cost of the board | $2,250,879 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies NeoGenomics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including NeoGenomics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exact Sciences Corporation | 2024 | Kevin Conroy | $1,083,368 | $13,496,138 | $0 | $712,329 | $15,539,378 |
| 2 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 3 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 4 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 5 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 6 | Maravai Life Sciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 7 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | NeoGenomics | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 9 | Adaptive Biotechnologies Corporation | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 10 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 11 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 12 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 13 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 14 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 15 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 16 | Emergent BioSolutions, Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
| 17 | OPKO Health, Inc. | 2025 | Phillip Frost | 960,000 | 0 | 400,000 | — | 1,854,000 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| NeoGenomics | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Adaptive Biotechnologies Corporation | 100% | RSU 50 · PSU 50 | No | Semler Brossy Consulting Group, LLC |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| CareDx, Inc. | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| Emergent BioSolutions, Inc. | 107% | Options 50 · PSU 50 | No | Willis Towers Watson |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Technologies, Inc. | 173% | PSU 50 · RSU 50 | No | Aon (January 1 to May 28) and Mercer (May 29 forward) |
| Maravai Life Sciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| OPKO Health, Inc. | not disclosed | not disclosed | not disclosed | None (no third-party compensation consultant has been engaged; internally generated peer group survey used instead) |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Tony Zook | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 2 | Section 01, Warren Stone | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 5,068,830. Filing ↗machine: r11 · c45 · span 896179–896188 |
| 3 | Section 01, Jeffrey Sherman | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 4,681,428. Filing ↗machine: r8 · c45 · span 887494–887503 |
| 4 | Section 01, Christopher Smith | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 4,045,937. Filing ↗machine: r5 · c45 · span 878169–878178 |
| 5 | Section 01, Melody Harris | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 3,692,445. Filing ↗machine: r20 · c45 · span 923703–923712 |
| 6 | Section 01, Alicia Olivo | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 3,049,999. Filing ↗machine: r14 · c45 · span 905528–905537 |
| 7 | Section 01, Gary Passman | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Summary Compensation Table” · page 52. As printed: 2,443,195. Filing ↗machine: r17 · c45 · span 914201–914210 |
| 8 | Section 03, Gary Passman PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r18 · c26 · span 1015389–1015396 |
| 9 | Section 03, Melody Harris RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t156 · r20 · c8 · span 922347–922356 |
| 10 | Section 03, Tony Zook PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r3 · c4 · span 719656–719663 |
| 11 | Section 03, Jeffrey Sherman OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r9 · c19 · span 985048–985055 |
| 12 | Section 03, Alicia Olivo OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r17 · c19 · span 1011014–1011021 |
| 13 | Section 03, Gary Passman RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r19 · c16 · span 1017492–1017498 |
| 14 | Section 03, Warren Stone OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r13 · c19 · span 998736–998742 |
| 15 | Section 03, Tony Zook OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r5 · c19 · span 972539–972546 |
| 16 | Section 03, Warren Stone RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r11 · c16 · span 991702–991708 |
| 17 | Section 03, Warren Stone OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r14 · c19 · span 1002048–1002055 |
| 18 | Section 03, Christopher Smith PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t133 · r4 · c1 · span 721274–721283 |
| 19 | Section 03, Jeffrey Sherman PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r7 · c26 · span 980174–980181 |
| 20 | Section 03, Warren Stone PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r10 · c26 · span 989599–989606 |
| 21 | Section 03, Alicia Olivo RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r16 · c16 · span 1007921–1007927 |
| 22 | Section 03, Gary Passman OPTION | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r20 · c19 · span 1021210–1021216 |
| 23 | Section 03, Jeffrey Sherman RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r8 · c16 · span 981952–981959 |
| 24 | Section 03, Warren Stone RSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r12 · c16 · span 995018–995024 |
| 25 | Section 03, Melody Harris PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r25 · c19 · span 1029954–1029961 |
| 26 | Section 03, Alicia Olivo PSU | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t162 · r15 · c26 · span 1006143–1006150 |
| 27 | Section 07, pay ratio | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “CEO Pay Ratio”. As printed: 93 : 1. Filing ↗machine: t184 · r2 · c2 · span 1381239–1381246 |
| 28 | Section 08, Dr. Alison Hannah | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 418,584. Filing ↗machine: t95 · r6 · c16 · span 512500–512507 |
| 29 | Section 08, Lynn Tetrault | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 365,150. Filing ↗machine: t95 · r4 · c16 · span 507903–507910 |
| 30 | Section 08, Michael Kelly | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 319,675. Filing ↗machine: t95 · r8 · c16 · span 516892–516899 |
| 31 | Section 08, David Perez | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 319,300. Filing ↗machine: t95 · r9 · c16 · span 519184–519191 |
| 32 | Section 08, Dr. Neil Gunn | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 312,500. Filing ↗machine: t95 · r10 · c16 · span 521279–521286 |
| 33 | Section 08, Felicia Williams | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 305,000. Filing ↗machine: t95 · r13 · c16 · span 528320–528327 |
| 34 | Section 08, Stephen Kanovsky | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 302,921. Filing ↗machine: t95 · r7 · c16 · span 514598–514605 |
| 35 | Section 08, Elizabeth Floegel | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 278,628. Filing ↗machine: t95 · r12 · c16 · span 525870–525877 |
| 36 | Section 08, Dr. Marjorie Green | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 256,832. Filing ↗machine: t95 · r5 · c16 · span 510202–510209 |
| 37 | Section 08, Anthony P. Zook | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 21,200. Filing ↗machine: t95 · r11 · c1 · span 522134–522140 |
| 38 | Section 08, Jack Kenny | DEF 14A | 2026-04-06 | 0001077183-26-000014 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 39 | Section 02, Greg D. Aunan 2026-05-01 | Form 4 | 2026-05-05 | 0001628280-26-030622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Greg D. Aunan 2026-05-01 | Form 4 | 2026-05-05 | 0001628280-26-030622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Greg D. Aunan 2026-05-01 | Form 4 | 2026-05-05 | 0001628280-26-030622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Alicia Olivo 2026-05-01 | Form 4 | 2026-05-05 | 0001628280-26-030621 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Greg D. Aunan 2026-05-01 | Form 4 | 2026-05-05 | 0001628280-26-030622 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Warren Stone 2026-05-02 | Form 4 | 2026-05-05 | 0001628280-26-030619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Warren Stone 2026-05-02 | Form 4 | 2026-05-05 | 0001628280-26-030619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Warren Stone 2026-05-02 | Form 4 | 2026-05-05 | 0001628280-26-030619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Warren Stone 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Alicia Olivo 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034620 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Alicia Olivo 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034620 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Alicia Olivo 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034620 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Warren Stone 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Warren Stone 2026-05-11 | Form 4 | 2026-05-13 | 0001628280-26-034619 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Lynn Tetrault 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, David Perez 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, David Perez 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, David Perez 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael Kelly 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040574 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Dr. Marjorie Green 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Felicia Williams 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040579 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Michael Kelly 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040574 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Dr. Neil Gunn 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040572 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Dr. Neil Gunn 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040572 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Michael Kelly 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040574 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Jack Kenny 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040581 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Jack Kenny 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040581 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Felicia Williams 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040579 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Lynn Tetrault 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Stephen Kanovsky 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040573 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Dr. Neil Gunn 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040572 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Dr. Neil Gunn 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040572 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Lynn Tetrault 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Stephen Kanovsky 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040573 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Dr. Marjorie Green 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Dr. Marjorie Green 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, David Perez 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040576 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Michael Kelly 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040574 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Stephen Kanovsky 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040573 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Stephen Kanovsky 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040573 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Dr. Marjorie Green 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Jack Kenny 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040581 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jack Kenny 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040581 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Felicia Williams 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040579 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Felicia Williams 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040579 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Lynn Tetrault 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040578 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Lynn Tetrault 2026-06-09 | Form 4 | 2026-06-11 | 0001628280-26-042506 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Lynn Tetrault 2026-06-15 | Form 4 | 2026-06-17 | 0001628280-26-043875 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Carolyn S. Starrett 2026-06-23 | Form 4 | 2026-06-25 | 0001628280-26-045501 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Carolyn S. Starrett 2026-06-23 | Form 4 | 2026-06-25 | 0001628280-26-045501 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 06, 2026 vote | Form 8-K | 2026-05-22 | 0001628280-26-037735 | Item 5.07 · say-on-pay result. As reported: 83.2% (votes for as printed: 91,781,833). Filing ↗ |
| 90 | Section 06, 2025 vote | Form 8-K | 2025-05-27 | 0001077183-25-000109 | Item 5.07 · say-on-pay result. As reported: 81.77% (votes for as printed: 87,823,189). Filing ↗ |
| 91 | Section 06, 2024 vote | Form 8-K | 2024-05-24 | 0001077183-24-000081 | Item 5.07 · say-on-pay result. As reported: 69.54% (votes for as printed: 76,045,753). Filing ↗ |
| 92 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 93 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 94 | Section 09b board cost (computed) | Computed | — | computed | Cash 639,048 + equity 1,611,831 + all other 0 = 2,250,879, summed across the director compensation table rows.machine: formula: Σ = 2,250,879 |
| 95 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 96 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 97 | Medpace Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001668397-26-000012 | CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. Filing ↗machine: t43 · r3 · c9 · span 495770–495781 |
| 98 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 99 | iRhythm Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 100 | Maravai Life Sciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai Life Sciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 101 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 102 | NeoGenomics (subject), Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics's own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 103 | Adaptive Biotechnologies Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 104 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 105 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 106 | CareDx, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 107 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 108 | Fulgent Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001674930-26-000020 | CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. Filing ↗machine: r3 · c22 · span 533279–533288 |
| 109 | Myriad Genetics, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0000899923-26-000031 | CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. Filing ↗machine: r2 · c24 · span 792987–792997 |
| 110 | Emergent BioSolutions, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001367644-26-000033 | CEO total compensation as printed in Emergent BioSolutions, Inc.'s own proxy. As printed: 5,321,147. Filing ↗machine: t155 · r3 · c15 · span 906918–906927 |
| 111 | OPKO Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197120 | CEO total compensation as printed in OPKO Health, Inc.'s own proxy. As printed: 1,854,000. Filing ↗machine: t21 · r4 · c25 · span 941666–941675 |
| 112 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 113 | Section 10a, CareDx, Inc. reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx, Inc. names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 114 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 115 | Section 10a, Fulgent Genetics, Inc. reciprocity | DEF 14A | — | 0001674930-26-000020 | Fulgent Genetics, Inc. names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 116 | Section 10a, Emergent BioSolutions, Inc. reciprocity | DEF 14A | — | 0001367644-26-000033 | Emergent BioSolutions, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 117 | Section 10a, Adaptive Biotechnologies Corporation reciprocity | DEF 14A | — | 0001193125-26-177409 | Adaptive Biotechnologies Corporation names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 118 | Section 10a, iRhythm Technologies, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 119 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc. names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 120 | Section 10a, Maravai Life Sciences Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai Life Sciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 121 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc. names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 122 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 123 | Section 10a, Medpace Holdings, Inc. reciprocity | DEF 14A | — | 0001668397-26-000012 | Medpace Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |
| 124 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc. names NeoGenomics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 125 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include NeoGenomics. Filing ↗ |